Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II LS001 in early to mid-stage Parkinson's disease
ChiCTR2200055707Phase 2Recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of levo-demethylphencynonate hydrochloride in Parkinson's disease (PD) (2 arms), sponsored by Xuanwu Hospital. Primary endpoints: Vital signs, Physical examination and 4 more. Started Jan 2022; status: recruiting.
02
Drugs
levo-demethylphencynonate hydrochloride
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ChiCTR2200055707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055707.